Ovarian cancer is a formidable adversary, ranking as the third most common gynecological cancer worldwide, with a five-year survival rate of only 40-45%. The battle against this disease begins with cytoreductive surgery, a complex procedure requiring multi-organ resection. However, the aftermath of this surgery is often marked by severe pain, a challenge that demands innovative solutions. Enter butorphanol, a synthetic opioid receptor agonist-antagonist, which has shown promise in suppressing visceral pain and reducing opioid-related side effects. But here's where it gets controversial: while butorphanol has been successfully used in laparoscopic hysterectomy and microwave ablation for liver tumors, its application in large open abdominal surgeries like ovarian cancer surgery remains uncharted territory.
This study aimed to explore the potential of butorphanol patient-controlled intravenous analgesia (PCIA) in managing postoperative pain in ovarian cancer patients. We hypothesized that butorphanol PCIA could provide effective pain relief while minimizing adverse reactions and stabilizing immune status, a crucial aspect considering the immune dysfunction often associated with tumors. The study design was meticulous: a prospective, double-blind, randomized controlled trial, approved by the Medical Research Ethics Committee and registered in the Chinese Clinical Trial Registry. Patients were divided into four groups based on the postoperative use of sufentanil or different doses of butorphanol PCIA.
The results were intriguing. High-dose butorphanol (4.0 μg·kg−1·h−1) PCIA demonstrated optimal analgesic outcomes, significantly reducing pain scores at 12 and 24 hours postoperatively compared to low-dose butorphanol. This high dose also resulted in a shorter time to early ambulation, suggesting improved recovery. Importantly, this dose did not increase the incidence of adverse events or significantly impact patient immune markers, indicating its safe application for postoperative analgesia. But here's a twist: while butorphanol did not significantly affect NK cell function, it did not show significant immunoenhancement effects either. However, moderate to high doses partially alleviated surgery-induced immunosuppression, suggesting a potential role in preserving perioperative immune function and improving clinical outcomes.
In conclusion, high-dose butorphanol PCIA effectively relieves postoperative pain and reduces the time to early ambulation in ovarian cancer patients without affecting immune indicators within 48 hours postoperatively. This study highlights the potential of butorphanol in ovarian cancer pain management, but also underscores the need for further research to fully understand its impact on immune function. The use of butorphanol in ovarian cancer patients should be carefully considered, weighing the benefits against potential risks, especially in the context of preserving perioperative immune function. And this is the part most people miss: while high-dose butorphanol PCIA may be an effective option for postoperative analgesia, it does not up-regulate immune function. This study opens the door to further exploration of butorphanol's role in ovarian cancer care, but also raises questions about its broader implications for immune modulation in cancer patients.
